HDT Bio is developing self-replicating RNA (repRNA) vaccines using its proprietary LION™ technology to enhance safety, potency, and durability for the treatment and prevention of infectious diseases and cancers. The company's platform addresses the limitations of traditional mRNA vaccines by providing increased efficacy and stability, enabling more effective responses to challenging health conditions.
Funding
$14.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional mRNA vaccines face challenges related to efficacy, stability, and manufacturing scalability, potentially limiting their effectiveness against infectious diseases and cancers. These limitations can hinder the development of broadly accessible and rapidly deployable vaccines.
Solution
HDT Bio is developing self-replicating RNA (repRNA) vaccines utilizing its proprietary LION™ technology to address the limitations of traditional mRNA vaccines. The repRNA approach amplifies the immune response, potentially leading to enhanced potency and durability. The LION™ delivery system further enhances safety and stability, while also offering manufacturing advantages. This platform aims to improve the treatment and prevention of infectious diseases and cancers by providing a more effective and scalable vaccine solution.
Target Audience
The primary target audience includes pharmaceutical companies, global health organizations, and government agencies involved in the development and distribution of vaccines for infectious diseases and cancer.
Features
- Self-replicating RNA (repRNA) technology for increased potency compared to traditional mRNA vaccines.
- LION™ delivery system for enhanced safety, stability, and manufacturability.
- Designed for rapid development and deployment in response to emerging health threats.
- Potential for improved immune response and long-lasting protection.